Anxiolytics: past, present, and future agents.
Although anxiety disorders were classified as neurotic disorders and not systematically studied before DSM-III, researchers and clinicians have been searching for effective, safe agents to treat anxiety symptoms and disorders for over a century. In that time, barbiturates, benzodiazepines, and many classes of antidepressants have been used as anxiolytics, all with side effect profiles that made them less than optimal treatments for anxiety. The recognition of the role of GABA in anxiety disorders has led researchers to develop anxiolytics that target GABA. The long-sought-after class of anxiolytics that are both effective and safe may be found in the new research being conducted with agents that selectively target GABA receptors and their subtypes.
Nemeroff
Charles B
CB
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga 30322, USA. cnemero@emory.edu
D014151:Anti-Anxiety Agents / Q000266:history / Q000494:pharmacology* / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000503:physiopathology; D005544:Forecasting; D018682:GABA Agents / Q000266:history / Q000494:pharmacology* / Q000627:therapeutic use; D049673:History, 20th Century; D006801:Humans; D018079:Receptors, GABA / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000187:drug effects / Q000502:physiology
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D018682:GABA Agents; D018079:Receptors, GABA; D005680:gamma-Aminobutyric Acid